Cure HHT Participates in PHA’s Associated Conditions Summit

Individuals with HHT have a greater risk of developing pulmonary hypertension. Statistically, 15-20% of HHT patients have PH. In November 2021, Cure HHT participated in the The Pulmonary Hypertension Association (PHA) Associated Conditions Partner Summit to explore ways to improve the understanding of PH and reduce barriers to diagnosis among at-risk groups, including those with…

Learn More >>

FREE Genetic Testing for Rare Diseases

The Rare Genomes Project is a patient-driven research project through the Broad Institute that performs full genome sequencing on families with suspected rare disease who do not have a genetic diagnosis. The goal of their project is two-fold: (1) provide access to testing for families that are genetically undiagnosed and (2) discover previously un-identified gene…

Learn More >>

PATH Clinical Trial – Now Recruiting!

The PATH Study is exploring the use of an oral medication called pomalidomide for the treatment of nosebleeds in HHT at up to 11 research centers across the United States. Find centers and check your eligibility.

Learn More >>
PH & HHT Brochure_title2

Cure HHT Participates in PHA’s Associated Conditions Summit


FREE Genetic Testing for Rare Diseases


PATH Clinical Trial – Now Recruiting!

Alexis - HHT Patient

HHT on the TODAY Show: “Mommy I love you. My head hurts.”

CHRN - Data Analysis 2021

Bedside to Bench: How the HHT Community Drives Research Initiatives (Recorded)

Cure HHT Store_webpost 1-01

Shop for a cause. Shop for a cure. Shop Cure HHT! 

Guidelines Series -12-Faughnan

International HHT Guidelines: Brain Vascular Malformations (VMs) (Recorded)

Liver Imaging_webinar2

Physician Webinar: The Role of Liver Imaging in HHT (Recorded)

Find Support

Connect with the Cure HHT community and find the latest resources including treatment centers, patient conferences, webinars and more.

Research for a Cure

Thanks to our supporters we're making exciting strides - gaining new insights into the cause, development and progression of this disease.

Who We Are

Constantly working for a brighter future for those with HHT through awareness, education and research - Cure HHT is the cornerstone of the HHT Community.

International HHT Guidelines


Find the most up-to-date resources to manage your HHT.

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome, is an inherited disease that leads to malformed blood vessels in multiple organs of the body and typically begins with nosebleeds during childhood. HHT can result in serious health problems if not promptly diagnosed and treated. Our mission is to find a cure for HHT while saving the lives and improving the well-being of individuals and families affected by HHT.

1 in
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of the blood vessels that affects approximately 1 in 5,000 people worldwide.
of people with HHT are undiagnosed